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We investigated the translational regulation of SCL pro-
tein expression and its role in hematopoietic lineage
choice. We show that the expression of different SCL
protein isoforms is regulated by signal transduction
pathways that modulate translation initiation factor
(eIF) function. A conserved small upstream open reading
frame (uORF) in SCL transcripts acts as a cis-regulatory
element for isoform expression. At the onset of erythroid
differentiation, truncated SCL protein isoforms arise by
alternative translation initiation and favor the erythroid
lineage. In comparison, full-length SCL proteins are
more efficient at enhancing the megakaryocyte lineage.
Together, our studies unravel translational control as a
novel mechanism regulating hematopoietic outcome.
Received October 9, 2002; revised version accepted February
18, 2003.
The basic helix–loop–helix (bHLH) transcription factor
SCL is essential for vertebrate hematopoiesis and vascu-
logenesis (Porcher et al. 1996). Deregulated expression of
the scl gene is among the most common molecular ab-
normalities found in human T-cell acute lymphoblastic
leukemia (T-ALL; for review, see Robb and Begley 1997).
Intriguingly, full-length and a number of smaller SCL
protein isoforms are expressed from mRNAs that con-
tain the entire SCL reading frame (Pulford et al. 1995).
Results presented here show that SCL protein isoforms
with various portions of the N terminus are differen-
tially expressed by a translation control mechanism. In
addition, we show that distinct SCL isoforms mediate
commitment and differentiation towards alternative he-
matopoietic lineages. It is intriguing that a similar situ-
ation exists with translationally controlled expression of
C/EBP and C/EBP isoforms that were shown to differ-
entially recruit various chromatin remodeling and basic
transcription factors to decisively affect proliferation and
differentiation (Kowenz-Leutz and Leutz 1999; Calk-
hoven et al. 2000; Pedersen et al. 2001). Our data show
that the expression of major hematopoietic transcription
factors is translationally controlled and that this type of
regulation plays an important role in hematopoiesis.
Results and Discussion
Expression of truncated SCL protein isoforms
is induced upon erythroid differentiation
Erythroid differentiation is induced by inactivation of a
temperature sensitive (ts) v-erbB oncogene kinase in the
chicken HD3 erythroblast cell line (Beug et al. 1982).
Similarly, in the human erythroid leukemia cell lines
HEL or TF-1 erythroid differentiation is induced by
DMSO and erythropoietin, respectively. In all three
cases, we observed the appearance of faster migrating
SCL peptides in addition to the full-length proteins after
induction of differentiation, as shown in Figure 1A and
B. The appearance of different SCL isoforms was altered
by drugs that interfere with different signaling pathways
that regulate translation initiation (De Benedetti and Ba-
glioni 1983; Gingras et al. 2001). Rapamycin (Rap, inhibi-
tor of mTOR) inhibits the appearance of short isoforms
in erythroid cells (Fig. 1A), whereas 2-amino purine
(2AP, inhibitor of eIF2-kinases) represses long isoforms
(Fig. 1B). Moreover, transient expression of full-length
human SCL cDNA in COS1 cells yields a similar iso-
form pattern that was also rapamycin sensitive (Fig. 1C).
The notion that SCL isoforms are generated by differen-
tial translation initiation was further supported by the
observation that 5-truncated cDNAs, which permit ini-
tiation from consecutive downstream AUG-codons,
comigrate with the isoforms observed in HD3 or HEL
cells (Fig. 1A,C). These results indicate that translational
up-regulation of truncated SCL isoforms occurs early in
erythroid differentiation, and that translational control
of SCL-isoform expression is conserved in vertebrates.
The eukaryotic translation initiation factors eIF2 and
eIF4E are rate limiting and decisive for regulated initia-
tion of translation of a subset of mRNAs that have cis-
regulatory small upstream open reading frames (uORFs;
Calkhoven et al. 2000, 2002; Morris and Geballe 2000;
Dever 2002). To further examine the effect of translation
initiation factor activity on SCL-isoform expression, a
kinase-inactive and dominant-negative form of the
eIF2-kinase PKR (PKR6) that results in hypophos-
phorylation and constitutive activation of eIF2 (Koromi-
las et al. 1992), or the cap-binding eIF4E were cotrans-
fected with HA-tagged SCL in HEK293A cells. Figure 2A
shows that activation of eIF2 by PKR6 or overexpres-
sion of eIF4E both enhance expression of truncated SCL
isoforms C and D and an isoform that initiates at an
alternative CUG-codon (Fig. 2A; ). Similarly, retroviral
transfer of PKR6 or eIF4E into HD3 cells enhanced ex-
pression of the endogenous SCL isoforms C and D (Fig.
2B). Expression of PKR6 in HEL cells results in a shift
in SCL-isoform expression towards more truncated iso-
forms (Fig. 2C). Analysis of polyA+ RNA by Northern
blotting showed that the scl-splicing pattern was not al-
tered by either PKR6 or eIF4E expression in HD3 or
HEL cells. Hence, activation of translation initiation by
enhancing eIF2 or eIF4E function favors expression of
truncated SCL isoforms.
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Differential expression of SCL isoforms depends
on conserved mRNA features
The structure of the SCL gene with respect to composi-
tion of coding exons and their boundaries is highly con-
served (Göttgens et al. 2000). As shown in Figure 1D,
three in-frame translation initiation sites designated A,
B, and C lie on the same exon IV, whereas initiation site
D lies on exon V (Fig. 1D; human exon nomenclature).
All but one mRNA splice variants converge on the non-
coding exon III. Exon III carries a highly conserved uORF
in front of the first SCL initiation codon on exon IV
(Aplan et al. 1990). The uORF is out-of-frame with re-
spect to the SCL reading frame (initiation site ), over-
laps the first SCL initiation A-site, and terminates up-
stream of the second initiation B-site (Fig. 1D).
To analyze a potential regulatory function of the uORF
in SCL-isoform generation and to rule out a proteolytic
origin of SCL isoforms, we used a mutagenesis approach
as described previously for the analysis of the transla-
tional control of C/EBP and C/EBP (Calkhoven et al.
2000). First, we determined whether the small SCL-
uORF serves as a cis-regulatory element in SCL protein
isoform expression (Fig. 3A). The uORF was either de-
stroyed by deleting its initiation site (), or converted
into a weaker initiation site (−) or an optimal initiation
site (+) and compared to the wild-type uORF (wt). As
shown in Figure 3A, alteration of uORF initiation site
strength drastically alters the distribution of SCL iso-
forms: Increasing the initiation strength at the uORF
(+) enhances expression of truncated SCL isoforms. In
contrast, reducing initiation strength (−), or removal of
the uORF initiation site (), diminishes or nearly abol-
ishes expression of truncated isoforms, respectively. In
addition, removal of the uORF also abrogates rapamycin
and 2-amino purine sensitivity (data not shown). Muta-
tions of the initiation sites of SCL isoforms into nonini-
tiation sites (Fig. 3B, A, B, and C) abolished ex-
pression of the corresponding SCL isoforms. Notably,
mutations that abrogated expression from upstream ini-
Figure 1. Translational controlled differential expression of SCL protein isoforms during erythroid differentiation. (A) Erythroid differentiation
in HD3 erythroblasts was induced by temperature shift (37°C–42°C for 12 h) to inactivate ts-v-erbB. (Left) Rapamycin was added 6 h after
temperature shift where indicated. (Right) Expression of individual SCL isoforms from sequential translation initiation codons revealed by 5
deletion of chicken SCL cDNA (termed A–D) in COS-1 cells. SCL-isoform expression was quantified by densitometry of X-ray films and
normalized values are depicted below. For immunodetection, specific antiserum against C terminus of chicken SCL was used. (B) Human TF-1
or HEL cells were treated for 4–48 h with Epo or DMSO, respectively, to induce erythroid differentiation. 2-Amino purine (2AP) was added
where indicated. Immunodetection of SCL in total cell extracts of TF-1 (data shown for 0 and 4 h postinduction) or HEL cells using a human
SCL C terminus-specific antiserum is shown. In HEL cells, the SCL-D isoform was obscured by a nonspecific band and was therefore omitted.
(C) Transiently transfected COS-1 cells with HA-tagged human SCL cDNA (left panel), and N-terminal-SCL deletion constructs (A–D, right
panel). Cells were treated with rapamycin (Rap), or mock (− −) treated for 24 h where indicated. For immunodetection of SCL, an HA-
immunotag-specific antiserum was used. SCL protein bands (), an alternative CUG (), and nonspecific/unidentified bands (*) are indicated.
(D) Representation of the conserved vertebrate scl structure and translation initiation sites. Numbering of exons follows the nomenclature for
the human scl gene. The SCL coding region is depicted in gray, the upstream open reading frame (uORF) is depicted in black. Potential
translation initiation AUG-sites are designated A–D for SCL and  for the uORF. Shading in the initiation sites comparison indicates critical
nucleotides at position −3 and +4 according to the optimal Kozak translation initiation consensus sequence (Kozak 1991).
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tiation sites (A, B) simultaneously enhanced expres-
sion from downstream initiation sites. Introduction of a
novel initiation codon between sites B and C, designated
site X (Fig. 3B), generated a novel peptide at the expense
of the isoform initiated at site C. Importantly, also ex-
pression from the engineered site X was abolished when
the uORF was destroyed (Fig. 3B). These results are in
accordance with differential translation initiation by a
ribosomal scanning and reinitiation mechanism but are
not compatible with a proteolytic mechanism of SCL-
isoform generation. In summary, these data show that
the SCL uORF directs expression of SCL isoforms.
Differential SCL-isoform expression determines
megakaryocytic versus erythroid lineage outcome
Regulated expression of various SCL isoforms during
erythroid differentiation suggested distinct biological
functions of individual isoforms. Indeed, retroviral trans-
fer of SCL-A isoform in the HEL cell line results in a
strong increase of cells that express the megakaryocytic
cell surface marker CD41a, whereas the truncated
SCL-D isoform failed to do so (Fig. 4A). These results
indicated that the long SCL isoforms preferentially sup-
ports megakaryopoiesis.
Differential functions of long versus short isoforms in
hematopoiesis were further assessed by introducing the
full-length SCL-A isoform, the truncated SCL-D isoform,
or a negative control into mouse bone marrow cells by
retroviral gene transfer (Fig. 4B). As shown in Figure 4C,
the frequency of megakaryocyte colonies was increased
threefold by SCL-A, whereas SCL-D was not efficient in
inducing megakaryocyte colony formation (Fig. 4C). In
Figure 3. The uORF of SCL controls translation initiation at alter-
native initiation sites. COS-1 cells were transiently transfected with
SCL constructs and analyzed by immunoblotting using HA-epitope-
specific antiserum. (A) The wild-type uORF initiation site (wt) was
compared to an optimized initiation context (+), a weakened con-
text (−), or a noninitiation site (). (B) Mutation of alternative
translation initiation sites affects SCL-isoform expression. Null ()
mutations of the individual initiation sites (A, B, or C) are shown. X
indicates an additional initiation site engineered between sites B
and C with the uORF initiation codon in wild-type context (X) or
removed (X). Schematic representations of the SCL mRNA with
initiation sites indicated in relation to the protein bands is shown at
the left. An alternative CUG initiation codon is depicted with an
arrowhead ().
Figure 2. The SCL protein isoform ratio is modulated by transla-
tion initiation factor activity. (A) HA-tagged SCL was cotransfected
with PKR6 (to activate eIF2), eIF4E, or control empty vector (−)
into HEK293A. SCL expression was analyzed by immunoblotting
using a HA-epitope-specific antiserum. The schematic representa-
tions of the SCL mRNA on the left indicate SCL initiation sites in
relation to the protein bands. An alternative CUG initiation codon
is depicted with an arrowhead (). (B) HD3 erythroblasts were in-
fected with retrovirus encoding PKR6, eIF4E, or a control vector (−)
and endogenous SCL was examined by immunoblotting using
chicken SCL-C terminus-specific antiserum. (C) HEL cells were in-
fected with PKR6 or control virus (−) and endogenous SCL expres-
sion was examined by immunoblotting using human SCL-C termi-
nus-specific antiserum. (Right) Expression of eIF4E transgene was
controlled by immunoblotting. eIF2-specific and eIF2 phosphory-
lation-specific antibodies (eIF2-P) were used to determine the effect
of PKR6 on eIF2. Because the antibody raised against human
eIF2 fails to detect the chicken homolog, a nonspecific band (*)
detected by the eIF2-P antibody serves as an internal control for the
loading of HD3 extracts. Northern blots of polyA+ RNA revealed no
alterations in scl RNA splicing pattern between control (−) and cells
expressing PKR6 or eIF2.
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comparison, the effect of SCL-A and SCL-D on multipo-
tent colonies was more modest (1.7- and 1.4-fold increase
over control, respectively). Alteration in erythroid differ-
entiation was examined by scoring for secondary ery-
throid colonies (CFU-E) derived from individual multi-
potent progenitor cells. As shown in Figure 4D, a strong
enhancement of CFU-E formation was observed with
SCL-D. Expression of the full-length SCL-A isoform in-
creased the number of CFU-Es only to some extent (Fig.
4D). Consistent with CFU-E colony assays, molecular
probing of cDNA samples derived from individual colo-
nies displayed highest -globin levels in SCL-D-isoform-
expressing cells (data not shown). Taken together, these
observations show that differential expression of alter-
native SCL isoforms determines cell fate during hema-
topoietic differentiation: SCL-D favors erythroid differ-
entiation, whereas the SCL-A isoform favors megakaryo-
cyte differentiation.
Translational control as a regulatory event
in hematopoietic cell fate determination
In addition to the bHLH domain, parts of the N-terminal
SCL sequences, including those involved in transactiva-
tion, are highly conserved between vertebrates suggest-
ing additional functions that have not yet been ad-
dressed. Our data show that differential expression of
SCL protein isoforms that contain various portions of
the N terminus modify lineage output in hematopoiesis.
Since distinct SCL isoforms arise from alternative initia-
tion sites, the data entail translational control as a regu-
latory event in hematopoietic cell fate determination.
The translational regulation of SCL depends on its
uORF. uORFs relay the activity of eukaryotic translation
initiation factors (eIFs) to determine initiation from al-
ternative sites (Fig. 5; Morris and Geballe 2000; Dever
2002). uORF-dependent initiation site selection by sens-
ing activities of eukaryotic initiation factors, eIF2 and
eIF4E, has also been observed with the “hematopoietic”
transcription factors, C/EBP and - (Calkhoven et al.
2000), and ATF4 (Harding et al. 2000; Morris and Geballe
2000). Components of the signaling pathways that con-
stitutively activate eIF4E and/or eIF2 display oncogenic
activity which can be blocked by drugs that interfere
with eIF functions (Aktas et al. 1998; Palakurthi et al.
2000; Aoki et al. 2001). It is therefore anticipated that
signaling pathways involved in adjusting the activity of
elFs, in particular the rate-limiting eIF4E and eIF-2, are
of major importance in hematopoiesis. Interestingly, in
acute myeloid leukemia or Down’s syndrome-related
acute megakaryocytic leukemia, the translationally con-
trolled transcription factors C/EBP and GATA1, respec-
tively, are targets for mutations that disrupt proper iso-
form expression (Pabst et al. 2001; Wechsler et al. 2002).
Figure 4. Functional differences between SCL protein isoforms in hematopoietic lineage outcome. (A) HEL cells were infected with the empty
pMSCVpuro vector (−), or vectors encoding the SCL-A or SCL-D isoform. After puromycin selection cells were analyzed for expression of the
megakaryocytic surface marker CD41a by flow cytometry. Data shown are the mean ± S.D. of two independent infections with analysis
performed in duplicates. All HEL cells expressed similar amounts of recombinant proteins (data not shown). (B) Mouse bone marrow cells were
infected with the empty pMSCV vector (−), or vectors encoding SCL-A (p42) or SCL-D (p22) isoforms. Recombinant SCL was detected in nuclear
extracts by immunoblotting with a monoclonal antibody against human SCL. The blot was stripped and reprobed with an anti-E12 antibody
as a control. (C) Increase of megakaryocyte colonies by full-length SCL-A. Mouse bone marrow cells were infected with the indicated retroviral
constructs, antibiotic (G418)-selected, and plated in methylcellulose culture under selective pressure. Colonies were scored on day 9 of culture.
Three independent experiments performed in duplicates are shown for each: control (open circles), SCL-A (gray circles), and SCL-D (black
circles); the mean is indicated by a bar. The differences between control, SCL-A, and SCL-D are significant (p < 0.05). (D) Increased numbers of
erythroid progenitors in multipotent colonies by SCL-D. Clonal analysis of erythroid development from multipotent progenitors. Mouse bone
marrow cells were infected with the indicated retroviral constructs, antibiotic (G418)-selected, and plated in methylcellulose culture supple-
mented with erythropoietin. On day 10, pluripotent colonies were individually picked and assayed for their contents in erythroid progenitors
(CFU-Es). The pluripotent colonies were ranked according to their capacities to give rise to increasing numbers of CFU-Es as shown. Note that
SCL-D colonies show the highest incident of CFU-Es. Data shown are typical of two independent experiments.
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Materials and methods
DNA constructs
SCL 5UTR (exon III) and coding sequences were isolated by reverse
transcriptase PCR (RT–PCR) from K562 cells. Constructs were C-termi-
nally tagged with HA-epitope and cloned in pSG5. All mutations were
generated on the SCLwt-HA-pSG5 by PCR or site-directed mutagenesis
using oligonucleotide primers containing the following mutated se-
quences: A, ACCATGGCC; B, ACCATGGCC; C, ACCATGGTG; D,
ACCATGTTC; E, ACCATGGAG; X, ACGGCCGAA→ ACCATGGAA;
, AGGATGACC→ AGGGGTACC; B, AGCATGGCC→ AGCGGG
GCC; C, CGCATGGTG→ CGCCACGTG; +, AATATGCCC→ ACC
ATGGCC; − −, AATATGCCC→ TGCATGCCC; , AATATGCCC→
AATATTCCC. Human SCL cDNAs, encoding A or D isoforms were
cloned into the EcoRI site of pMSCV-neo (Hawley et al. 1994). The mu-
rine -globin probe spans the 3UTR and was a generous gift from Dr.
Gordon Keller (Mount Sinai, New York; Robertson et al. 2000).
Cells and tissue culture
COS-1 and HEK293A cells (ATCC, CRL-1650) were propagated and
transfected as described in (Calkhoven et al. 2000). Cells were transfected
with 6 µg h-SCL-HA-pSG5, 2 µg PKR6-pSG5, or eIF4E-pSG5 and 2 µg
carrier pSG5 DNA using a calcium phosphate method. HD3 cells were
propagated in DMEM/8% FCS/2% chicken serum/50 µM -mercapto-
ethanol/10 mM HEPES at pH 7.4 at 37°C or 42°C. HEL and TF-1 cells
were propagated in RPMI/10% FCS (GIBCO) at 37°C. Erythroid differen-
tiation was induced by 1.5% DMSO for 2 d. HD3 and HEL cells were
infected with the retroviral PKR6-pMSCV or eIF4E-pMSCV expression
constructs as described in Calkhoven et al. (2000) using the GP2-293
virus producer cell line (Clontech). Rapamycin was used in a concentra-
tion of 1 µM, 2-amino purine was used in a concentration of 5 mM
(Calbiochem).
FACS analysis
For FACS analysis 2 × 105 cells were stained with FITC-conjugated an-
tihuman CD41a antibody (R&D systems). Control cells were treated
with IgGa-FITC. After staining with 1 µg/mL propidium iodide, cells
were examined on a FACSCalibur (Beckton Dickinson). Viability gates
were set by propidium iodide exclusion.
Bone marrow infection and colony assays
Bone marrow cells were collected from 5-fluorouracil-treated mice and
infected as described previously (Krosl et al. 1998). Cells were plated in
prestimulation medium (IMDM, supplemented with 15% fetal bovine
serum, 5 ng/mL IL-3, 100 ng/mL Steel factor, and 10 ng/mL IL-6) for 2 d.
Cells were then infected by cocultivation on confluent monolayers of
GP + E-86 cells in the presence of polybrene (8 µg/mL) for 48 h (Krosl et
al. 1998). Infection efficiency was in the range of 20%. Following infec-
tion, the cells were allowed to recover for 24 h, plated in semisolid
IMDM (0.8% methylcellulose, Fluka), supplemented with 10% fetal calf
serum (FCS, GIBCO), 50 ng/mL Steel factor, 100 ng/mL IL-11, 10 ng/mL
IL-6, Erythropoietin (1 U/mL), 2.7 × 10−5 M -monothioglycerol (Calbio-
chem), and 0.8 mg/mL Geneticin (G-418, GIBCO). Colonies were scored
on day 9, and multipotent colonies were individually picked. Multipo-
tent colonies were replated into methylcellulose culture, containing
erythropoietin (1 U/mL) to assay for late erythroid progenitors (CFU-E).
-globin gene expression was assessed by global amplification of cDNA
(Brady et al. 1995). Another batch of cells was taken after infection for
Western blot analysis of nuclear extracts. For megakaryocyte colony as-
says, mouse bone marrow cells were isolated, infected, preselected in
G418 for 5 d and plated in methylcellulose culture under selective pres-
sure. Colonies were scored on day 9. For statistic analysis, each sample
set (SCL-A or SCL-D) was compared to the control set (empty vector)
using t-test (paired two samples for mean).
Western blot analysis
Cell extracts were prepared and Western blot analysis was performed as
described (Calkhoven et al. 1994; Lecuyer 2002). The following antisera
were used: HA.11, BabCO (1:1000); SCL, Geneka Biotechnology (1:250),
human SCL, gift from Richard Baer (Department of Microbiology, South-
western Medical School, Dallas, TX); monoclonal human SCl, gift from
Daniele Mathieu-Mahul (Institut de Genetique Moleculaire, Montpel-
lier, France; 1:1000). eIF2 (C-20), Santa Cruz Biotechnology (0.5 µg/mL);
Phosphorylated-eIF2, Cell Signaling Technology (1:1000); eIF4E, Trans-
duction Laboratories (0.5 µg/mL). The chicken SCL antiserum was raised
against the C-term peptide HHAILPVEGSAQR in rabbits (1:1000). Pro-
tein bands were quantified by densitometry of X-ray films using the
FUJIFILM Science Lab/Image Gauge computer program.
Northern blot analysis
Northern analysis was performed as described in Kowenz-Leutz and
Leutz (1999) using 3 µg poly-A+ RNA and 700-bp C-terminal SCL coding
sequences as probes recognizing all known splice variants.
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